小智港股覆盤 | 6月13日
今日，港股三大指數集體下跌。截止收盤，恆生指數大跌3.39%，報21067點。國企指數大跌3.54%，報7340點。恆生科技指數大跌4.72%，報4598點。市場約415只個股上漲，1245只個股下跌。成交額突破1593.92億港幣，和昨天同期相比下跌11.62%。南下資金淨流入54.98億港幣。
盤面上，菸草板塊集體拉昇。思摩爾國際漲超4%。電子煙概念股逆市走強，思摩爾國際漲6.28%。
綜合消費服務板塊跟隨走強。新東方在線漲超39%；成實外教育漲超20%；澳洲成峯高教漲超15%；新東方-S漲超13%；金匯教育漲超10%。新東方在線漲幅擴大至43%，“雙語帶貨”促當日GMV突破千萬元；成實外教育盤中漲近29%，剝離K9業務後公司轉型輕資產模式。
電商板塊暴跌。京東健康跌超9%；阿裏巴巴-SW跌超7%；寶尊電商-SW、美團-W等多股跌超6%；香港科技探索跌超5%。大和升京東健康目標價7%至75港元，維持“買入”評級；香港科技探索(1137.HK)低開3.39%，5月訂單總額環比下降10.%至6.13億元。
互聯網醫療板塊全線走低。阿裏健康跌超7%；鷹瞳科技-B跌超6%；平安好醫生跌超4%；醫脈通、醫渡科技等多股跌超2%。中金：維持阿裏健康“跑贏行業”評級，目標價5.3港元；大和降平安好醫生目標價9%至22.75港元，維持“買入”評級。
生物科技板塊全線走低。開拓藥業-B跌超11%；榮昌生物-B跌超9%；百濟神州、永泰生物-B、和鉑醫藥-B等多股跌超8%。榮昌生物-B早盤再漲超16%，維迪西妥單抗治療尿路上皮癌最新數據亮眼；百濟神州：在2022年歐洲血液學協會年會上展示血液學產品組合和管線；和鉑醫藥-B漲3.02% B7H4x4-1BB雙特異性抗體新藥研究申請獲批。
uSMART智能寫手的信息、數據均來自媒體公開報道，智能寫手不能保證其完全準確，內容僅供參考，不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
